Ignite Creation Date:
2024-05-06 @ 7:48 PM
Last Modification Date:
2024-10-26 @ 3:14 PM
Study NCT ID:
NCT06141772
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-11-21
First Post:
2023-10-17
Brief Title:
Kinetics of Circulating Tumor DNA in Lymphoma Treated by Immuno-chemotherapy
Sponsor:
Centre Henri Becquerel
Organization:
Centre Henri Becquerel
Study Overview
Official Title:
Prospective Study of Circulating Tumor DNA Kinetics Post R-CHOP Type Treatment of Diffuse Large B Cell Lymphoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LYMPHO-CLEAR
Brief Summary:
The purpose of this study is to determine the kinetics of circulating tumor DNA ctDNA in the hours following initial administration of immuno-chemotherapy to patients with diffuse large B cell lymphoma DLBCL Modelizing the short-term kinetics of ctDNA would help to determine the optimal time-point for ctDNA follow-up The investigators hypothesize that the greater ctDNA release at this time-point compared to baseline might lead lead to the detection of novel variants compared to baseline
Detailed Description:
ctDNA in diffuse large B cell lymphoma DLBCL has become an essential dynamic biomarker Due to its short half-life ctDNA is a real-time reflection of tumoral evolution and is a non-invasive biomarker that can be used for patient evaluation and follow-up The quantity of ctDNA before treatment is correlated with tumoral mass international prognostic index IPI and prognosis The principal mechanism of ctDNA release is tumor cell apoptosis and it is well established that tumor cell apoptosis is observed in the hours following immuno-chemotherapy However the kinetics of ctDNA concentration in the hours following immuno-chemotherapy administration is unknown
Modelizing the kinetics of ctDNA during this early timeframe could help to better predict chemo-sensitivity and better reflect genetic heterogeneity of the tumor through release of a larger quantity of ctDNA compared to baseline
Modelizing the kinetics of ctDNA during this early timeframe could help to better predict chemo-sensitivity and better reflect genetic heterogeneity of the tumor through release of a larger quantity of ctDNA compared to baseline
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None